WifOR Institute, Darmstadt, 64283, Germany.
Steinbeis, School of International Business & Entrepreneurship (SIBE), Herrenberg, 71083, Germany.
J Comp Eff Res. 2020 Oct;9(14):1017-1026. doi: 10.2217/cer-2020-0131. Epub 2020 Oct 5.
In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. Health benefits, measured as an increase in progression-free survival, were translated into productivity gains in both paid and unpaid work using gross value added as productivity measure. From 2017 to 2030, 11,870 overall progression-free years can be gained by utilizing obinutuzumab. These progression-free years correspond to undiscounted productivity gains of about €187.9 million in paid work and about €535.9 million in unpaid work. Our study shows that the benefits of the use of obinutuzumab in the first-line treatment of follicular lymphoma extend beyond clinical advantages.
在这项研究中，我们评估了奥滨尤妥珠单抗联合化疗免疫治疗（G-chemo）在滤泡性淋巴瘤患者一线治疗中的增效作用。使用附加值作为生产力衡量标准，我们将健康效益（表现为无进展生存期的延长）转化为有偿和无偿工作中的生产力增益。从 2017 年到 2030 年，使用奥滨尤妥珠单抗可以获得总计 11870 年的无进展生存时间。这些无进展生存时间对应的是有偿工作中约 1.879 亿欧元和无偿工作中约 5.359 亿欧元的未贴现生产力收益。我们的研究表明，奥滨尤妥珠单抗在滤泡性淋巴瘤一线治疗中的应用带来的益处不仅限于临床优势。
